Roblox founder and CEO David Baszucki and his wife, Jan Ellison Baszucki, have committed $20 million to McLean Hospital in Belmont, Massachusetts, to establish a new clinical and research facility focused on metabolic psychiatry. Announced on October 21, 2026, through the couple's philanthropic organization, the Baszucki Group, the grant will fund the creation of the McLean Center for Metabolic Psychiatry. The initiative follows their son Matthew's personal recovery from severe bipolar disorder after adopting a medically supervised ketogenic diet.

The funding is designed to bridge the gap between nutrition, cellular energy metabolism, and mental health care. While according to The Times of India the grant is framed around studying whether diet-based therapies can improve bipolar disorder and general mental health, the formal announcement via Business Wire and reporting by Becker's Behavioral Health describe a broader mandate. The investment will support direct clinical care, scientific research, and medical education and training initiatives co-led by MH², addressing multiple psychiatric conditions including bipolar disorder, major depression, and schizophrenia.

A Family Struggle Drives Philanthropic Investment

The financial commitment stems directly from the Baszucki family's experience navigating the traditional mental health system with their son, Matthew Baszucki, now 30 years old. According to VPM / NPR, Matthew was diagnosed with bipolar disorder and endured multiple psychiatric hospitalizations, consulted dozens of mental health providers, and was prescribed more than a dozen different medications. At one point during his illness, he left home in a psychotic state and slept on the streets of Los Angeles.

Seeking additional options, Jan Ellison Baszucki contacted Dr. Chris Palmer, a Harvard psychiatrist, after hearing him discuss ketogenic therapy for bipolar disorder on a podcast. Although Palmer initially hesitated because he was not accepting new patients, he agreed to consult with the family. Under Palmer's supervision, Matthew adopted a medical version of the ketogenic diet—a nutritional regimen high in fat and low in carbohydrates that has been used by physicians for decades to manage drug-resistant epilepsy.

Speaking on the Baszucki family's Metabolic Mind podcast in June, Matthew explained that after roughly four months on the ketogenic regimen, his symptoms subsided, allowing him to sleep normally and avoid states of mania and delusion. "My brain felt like it could work again," he recalled, noting that he was eventually able to gradually taper his medications under medical guidance.

While Matthew's experience proved transformative for his family, clinicians emphasize that an individual recovery represents an anecdote rather than broad proof of clinical efficacy. The new McLean center aims to subject these observations to rigorous, controlled clinical trials.

Understanding Metabolic Psychiatry and Brain Energy

McLean Hospital, a psychiatric teaching hospital that is part of the Mass General Brigham health care system, claims the new facility will be the first center of its kind in the United States. It will anchor the newly launched Global Network for the Advancement of Metabolic Psychiatry (MetPsy), an organization aiming to connect clinicians and researchers worldwide.

Dr. Dost Öngür, chief of the psychotic disorders division at McLean and director of the new center, spoke with The Boston Globe about the biological mechanisms behind the emerging field. Metabolic psychiatry examines the intersection of cellular energy metabolism and psychiatric conditions. Over the past decade, scientific studies have identified abnormalities in how the brain produces and uses energy in individuals with severe mental illnesses like schizophrenia and bipolar disorder.

"The brain actually is the most energy-hungry organ in our bodies. It burns the most energy, gram for gram, of any of our organs," Öngür explained. Because information processing, consciousness, and behavior generation are highly energy-intensive, any disruption in energy supply at the cellular level can impair healthy brain function. Researchers hypothesize that correcting these metabolic abnormalities—whether through targeted nutritional protocols like the ketogenic diet or other metabolic interventions—could help stabilize psychiatric symptoms.

Öngür also noted that genetics and innate biological characteristics play a significant role in how effectively different individuals extract energy from food, meaning diet is only one piece of a complex physiological puzzle.

Expanding the Research Footprint

The $20 million grant to McLean Hospital is the latest in a series of major financial commitments by the Baszucki family toward mental health and neuroscience. According to a profile by Lifestyles Magazine, the couple's cumulative philanthropic giving has surpassed $170 million.

Their previous mental health investments include joining Google co-founder Sergey Brin and investor Kent Dauten in 2022 for a combined $150 million pledge toward bipolar disorder research and treatment, though the Baszuckis' individual share of that pooled commitment was not separately itemized. In addition, the family has funded a $6 million study at the University of Pittsburgh examining the ketogenic diet's effects on bipolar disorder, a $3 million endowed chair in metabolic neuroscience at Stony Brook University, and $2 million in separate support for McLean Hospital's ReThink Bipolar clinical trial.

What Patients and Families Should Know

As interest in nutritional psychiatry grows, researchers and public health experts stress the need for clinical caution. While early observational data and patient reports regarding ketogenic therapies are encouraging to researchers, metabolic psychiatry remains an developing field.

The primary goal of the McLean Center for Metabolic Psychiatry is to conduct formal clinical trials to determine which specific metabolic or dietary interventions work for which patient populations, and at what stage of their illness. Patients currently managing bipolar disorder, schizophrenia, or major depression should never alter or discontinue prescribed psychiatric medications or attempt restrictive medical diets without direct supervision from their treating physician and a qualified clinical care team.

Frequently Asked Questions

When will the new McLean Center for Metabolic Psychiatry open to patients?

While the $20 million grant and the creation of the center were formally announced on October 21, 2026, Becker's Behavioral Health notes that the hospital's announcement did not specify an exact opening date for clinical operations or a start date for its initial clinical trials.

How will the $20 million grant be utilized?

The funding is designated to build a program combining direct patient clinical care, controlled clinical trials, and medical education and physician training initiatives co-led by MH². The exact financial breakdown among these individual departments has not yet been disclosed.

Will the center only study the ketogenic diet for bipolar disorder?

No. While ketogenic therapy and bipolar disorder are central areas of interest, McLean leaders stated the center's scope will encompass broader metabolic interventions and examine how cellular energy affects several serious psychiatric conditions, including depression and schizophrenia.

Sources